EVT-101
![]() | |
Clinical data | |
---|---|
Synonyms | ENS-101 |
Drug class | NMDA receptor antagonist |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C16H13F3N4 |
Molar mass | 318.303 g/mol |
3D model (JSmol) | |
| |
|
EVT-101, also known as ENS-101, is an experimental medication which originated from Roche and is under development by Evotec AG for the treatment of major depressive disorder.[1] It acts as a selective NMDA receptor subunit 2B (NR2B) antagonist.[1][2] As of November 2017, EVT-101 is in phase II clinical trials for major depressive disorder, although no recent reports of development have been identified.[1] The drug was first claimed by Roche in 2002.[3]
See also
References
- 1 2 3 http://adisinsight.springer.com/drugs/800023880
- ↑ https://www.evotec.com/uploads/media_library/14/AC_SfN_Poster_2010_FINAL.pdf
- ↑ Santangelo RM, Acker TM, Zimmerman SS, Katzman BM, Strong KL, Traynelis SF, Liotta DC (2012). "Novel NMDA receptor modulators: an update". Expert Opin Ther Pat. 22 (11): 1337–52. doi:10.1517/13543776.2012.728587. PMC 3677696. PMID 23009122.
External links
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.